The present study demonstrated that EMPA treatment could attenuate HFD-induced NAFLD by activating Sesn2-mediated AMPK-mTOR signaling; this alleviated abnormal hepatic function and inflammation. Here, SESN2 is linked to metabolic dysfunction-associated steatotic liver disease.